Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 736 to 750 of 1553 results for do not do recommendations

  1. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis.

    Highly specialised technologies guidance
    Published
    22 May 2019
    View recommendations

    Sections for HST9

  2. Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy at thresholds specified by the company, or the prognostic ability of MRE to predict clinical outcomes (see section 3.20 ).

    Recommendation ID DG50/02 Question Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results

    Research recommendation
    Published
    3 February 2023

  3. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

    Highly specialised technologies guidance
    Published
    23 April 2025

    Sections for HST33

  4. At what gestation should treatment with prophylactic vaginal progesterone for the prevention of preterm birth be started and stopped?

    Recommendation ID NG25/7 Question At what gestation should treatment with prophylactic vaginal progesterone for the prevention of preterm

    Research recommendation
    Published
    25 October 2019

  5. Information needs for children and young people:- during their care pathway to diagnosis of food allergy:- What do children and young people with IgE-mediated food allergy and their parents or carers want to know during the process of diagnosis and how is this demand best met?

    Recommendation ID CG116/3 Question Information needs for children and young people:- during their care pathway to diagnosis of food...

    Research recommendation
    Published
    9 June 2015

  6. Care and support planning:- What are the most effective methods of care planning for people who do not have regular contact with an informal carer?

    Recommendation ID NG97/5 Question Care and support planning:- What are the most effective methods of care planning for people who...

    Research recommendation
    Published
    10 December 2018

  7. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

    Highly specialised technologies guidance
    Published
    10 January 2024
    View recommendations

    Sections for HST30

  8. NICE health technology evaluation topic selection: the manual (PMG37)

    This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance

  9. What information and support do people with diverticulosis, diverticular disease or acute diverticulitis need?

    Recommendation ID NG147/4 Question What information and support do people with diverticulosis, diverticular disease or...

    Research recommendation
    Published
    10 February 2020

  10. Glycated haemoglobin testing:- Does optimisation of HbA1c in people with poorly controlled diabetes improve surgical outcomes?

    Recommendation ID NG45/3 Question Glycated haemoglobin testing:- Does optimisation of HbA1c in people with poorly controlled diabetes...

    Research recommendation
    Published
    4 May 2016

  11. NICE recommended that further research should be designed to generate robust evidence of the clinical- and cost-effectiveness of Holoclar for treating both eyes in people with bilateral limbal stem cell deficiency after eye burns if they do not have enough tissue for a conjunctival limbal autograft. The study should recruit people with bilateral disease and evaluate the effectiveness of treatment in both eyes. Outcomes should include transplant success and assessments of health-related quality of life using a generic preference-based measure.

    Recommendation ID TA467/2 Question NICE recommended that further research should be designed to generate robust evidence of the clinical-

    Research recommendation
    Published
    15 October 2018

  12. What structured group activities are effective at improving interpersonal functioning (social skills) for people with complex psychosis?

    Recommendation ID NG181/4 Question What structured group activities are effective at improving interpersonal functioning (social skills)

    Research recommendation
    Published
    26 October 2020

  13. Delirium assessment tools:What is the diagnostic accuracy, and ease of implementation, of different delirium assessment tools: for people with pre-existing cognitive impairment, for example dementia, learning disability or severe depression for people who do not speak English as a first language in different settings, for example emergency departments, residential care homes or virtual consultations when delivered by different types of health and social care practitioners, for example healthcare assistants or allied health professionals such as paramedics?

    Recommendation ID CG103/01 Question Delirium assessment tools:What is the diagnostic accuracy, and ease of implementation, of different

    Research recommendation
    Published
    3 February 2023

  14. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

    Technology appraisal guidance
    Published
    4 October 2023
    View recommendations

    Sections for TA915

  15. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA350